Abstract
Background
Occlusion of the anterior cerebral artery (ACA) is uncommon but may lead to significant disability. The benefit of endovascular treatment (EVT) for ACA occlusions remains uncertain.
Methods
We included patients treated with EVT and compared patients with ACA occlusions with patients who had internal carotid artery (ICA) or proximal (M1/M2) middle cerebral artery (MCA) occlusions from the MR CLEAN Registry. Primary outcome was the modified Rankin Scale score (mRS). Secondary outcomes were functional independence (mRS 0–2), National Institutes of Health Stroke Scale (NIHSS) score, delta-NIHSS (baseline minus NIHSS score at 24–48 h), and successful recanalization (expanded thrombolysis in cerebral infarction (eTICI) score 2b-3). Safety outcomes were symptomatic intracranial hemorrhage (sICH), periprocedural complications, and mortality.
Results
Of 5193 patients, 11 (0.2%) had primary ACA occlusions. Median NIHSS at baseline was lower in patients with ACA versus ICA/MCA occlusions (11, IQR 9–14; versus 15, IQR 11–19). Functional outcome did not differ from patients with ICA/MCA occlusions. Functional independence was 4/11 (36%) in patients with ACA versus 1949/4815 (41%) in ICA/MCA occlusions; median delta-NIHSS was − 1 (IQR − 7 to 2) and − 4 (IQR − 9 to 0), respectively. Successful recanalization was 4/9 (44%), versus 3083/4787 (64%) in ICA/MCA occlusions. Mortality was 3/11 (27%) versus 1263/4815 (26%). One patient with ACA occlusion had sICH; no other complications occurred.
Conclusion
In this cohort ACA occlusions were uncommon. Functional outcome did not differ between patients with ACA occlusions and ICA/MCA occlusions. Prospective research is needed to determine feasibility, safety, and outcomes of EVT for ACA occlusions.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
Introduction
Acute ischemic stroke (AIS) as a result of isolated primary occlusion of the anterior cerebral artery (ACA) accounts for only 0.5–3% of all strokes [1] but may lead to significant handicap. Patients typically present with contralateral weakness of the leg and may suffer cognitive deficits and behavioral changes due to ischemia in limbic and frontal areas of the brain [2]. Occasionally, contralateral weakness of the face and arm is present when the medial lenticulostriate arteries are involved[3]. Since the publication of five large trials in 2015, [4,5,6,7,8] endovascular treatment (EVT) has become standard care for AIS due to proximal anterior circulation occlusions[9]. However, the majority of patients in the EVT trials had an internal carotid artery (ICA) or proximal middle cerebral artery (MCA) occlusion. Of all 5 trials, only the Multicenter Randomized Clinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands (MR CLEAN) allowed inclusion of patients with ACA occlusions, and only three such patients were included[4]. As such, the benefit of EVT for ACA occlusions remains uncertain and data on treatment outcomes in clinical practice are scarce. Observational data suggest that EVT for these patients is safe and feasible, but the reported number of patients is limited [10,11,12,13]. Current guidelines do not provide clear recommendations for ACA occlusions and treatment for these patients varies between countries, centers, and interventionalists[14]. The aim of this study was to describe the results and outcome of EVT in patients with primary ACA occlusions using a large Dutch national EVT registry [15].
Methods
Study design
The MR CLEAN Registry is a multicenter, nationwide, prospective, consecutive database of patients treated with EVT for AIS in the Netherlands. Patients were included if they underwent arterial puncture with the intention to perform EVT for AIS. The choice of EVT technique and device was left to the treating interventionalist. Radiological baseline and follow-up imaging were centrally adjudicated by an independent core laboratory of trained physicians blinded to all clinical and treatment data except for symptom side. The MR CLEAN Registry study protocol was evaluated by the ethics committee of the Erasmus MC, University Medical Centre, Rotterdam, the Netherlands (MEC-2014-235). Permission to carry out the study as a registry was granted.
We used data of patients treated between March 16, 2014, from the first patient treated after the MR CLEAN trial [4], and January 1, 2019. We compared patients with ACA occlusions on computed tomography angiography (CTA), aged 18 years or older, who were treated in a MR CLEAN trial center, with patients with occlusion of the ICA or proximal MCA (M1 and M2 parts). Patients with secondary (periprocedural) occlusion of the ACA or additional occlusions in different vascular territories were excluded.
Outcome measures
Our primary outcome was functional outcome measured on the modified Rankin Scale (mRS, ranging from 0, no symptoms, to 6, death) at 90 days after stroke onset. Secondary clinical and radiological outcomes were 90-day functional independence (mRS 0–2), National Institutes of Health Stroke Scale (NIHSS) score at 24–48 h, delta-NIHSS (baseline NIHSS minus NIHSS score at 24–48 h), NIHSS improvement (\(\ge\) 4 NIHSS points improvement between baseline and 24–48 h), and successful reperfusion (expanded thrombolysis in cerebral infarction (eTICI) score 2b–3). Safety outcomes were 90-day mortality, symptomatic intracranial hemorrhage (sICH), peri-operative complications (vessel perforation, dissection), and neurological deterioration (\(\ge\) 4 NIHSS points worsening between baseline and 24–48 h).
Statistical analysis
All analyses were descriptive because of the low number of patients with ACA occlusions. Summary statistics are presented as mean with standard deviation for normally distributed data, and median with interquartile range (IQR) for non-normally distributed data. We compared outcomes of patients with ACA occlusions with those of MR CLEAN Registry patients with ICA or proximal MCA occlusions. For binary categorical outcomes, Fisher’s exact test was used in case of expected counts of zero and Chi-Square test if there were no expected counts of zero. For ordinal outcomes, the Chi-Square test for trend was used. For the semi-continuous outcome measure of delta-NIHSS, which was non-normally distributed, the Kruskal–Wallis test was used. Missing data were not imputed. The level of significance was set at p < 0.05. All statistical analyses were performed with IBM SPSS Statistics version 23.0.0.0 (New York, NY, United States 2017).
Data availability
In compliance with the General Data Protection Regulation, source data will not be made available for other researchers. Analytic methods, study materials, scripts of the statistical analyses, and their output are available from the corresponding author on reasonable request.
Results
In total, 5193 patients were included in the MR CLEAN Registry between March 16, 2014 and January 1, 2019. Data on the site of occlusion on baseline CTA were missing for 210/5193 (4.0%) patients. Only 11 patients (0.2%) had a primary ACA occlusion on CTA at admission. Four out of 11 patients had a occlusion in the A1 segment (36%) and seven patients in the A2 segment (64%) (Fig. 1). In patients with ACA occlusions, median age was 69 (IQR 65–74 years) versus 72 (IQR 62–81) in patients with ICA or MCA occlusions. Three (27%) patients with ACA occlusions were female versus 2396 (48%) in the ICA/MCA group. Median NIHSS score on admission was lower in patients with ACA occlusions (11, IQR 9–14) compared to patients with ICA or MCA occlusions (15, IQR 11–19; Table 1).
Functional outcomes
Functional outcome at 90 days after AIS did not differ between patients with ACA occlusions and those with ICA or MCA occlusions (Fig. 2). Four of 11 patients (36%) with ACA occlusions were functionally independent at 3 months, versus 1949/4815 (41%) patients with.
ICA or MCA occlusions (Table 2). In patients with ACA occlusions, median NIHSS score at 24–48 h after AIS onset was 11 (IQR 2–13) with a median delta-NIHSS of -1 (IQR -7 to 2). In patients with ICA or proximal MCA occlusions, median NIHSS score at 24–48 h after AIS onset was 9 (IQR 3–17) with a median delta-NIHSS of -4 (IQR -9 to 0). Three of 9 patients (33%; 2 missing data) in the ACA group showed improvement of ≥ 4 points on the NIHSS versus 2427/4518 patients (54%) in the ICA or MCA group.
Radiological outcomes
Successful recanalization was achieved in 4/9 (44%) of patients with ACA occlusions (Table 2). Of these patients, 2/4 (50%) were functionally independent at 3 months versus 2/5 (40%) of patients with partial or no recanalization. Successful recanalization was achieved in 3083/4787 (64%) of patients with ICA or proximal MCA occlusions. Of these patients, 1451/2977 (49%) achieved functional independence at 3 months versus 418/1656 (25%) of patients with partial or no recanalization. Procedural characteristics are shown in Table 3.
Safety outcomes
Mortality at 90 days was 27% (3/11) in the ACA group versus 26% (1263/4815) in patients with ICA or MCA occlusions (Table 2). One of 11 patients (9%) in the ACA group had sICH, and one patient (9%) deteriorated ≥ 4 points on the NIHSS. No periprocedural dissection or perforation occurred in this group. In patients with ICA or proximal MCA occlusions, 294/4972 (6%) had sICH, periprocedural dissection occurred in 77/4330 (2%), and 65/4318 (2%) suffered peri-procedural perforation.
Discussion
In this Dutch national cohort of EVT-treated patients, ACA occlusions were uncommon, occurring in only 0.2% of 4983 patients. Complication rates and functional outcomes of patients with ACA occlusions were similar to those of patients with ICA or proximal MCA occlusions. However, analyses were limited by the small ACA sample size. Successful reperfusion was achieved in less than half of patients with ACA occlusions.
Even though ACA occlusions were an inclusion criterion in the MR CLEAN trial, less than 1% of patients in the subsequent MR CLEAN Registry were treated for ACA occlusions. As ACA occlusions may account for up to 3% of all stroke cases, [1] this suggests under-treatment and possibly under-recognition of ACA occlusions. The uncertainty of the available evidence and lack of consensus on the benefit of EVT for ACA occlusions in stroke may have negatively impacted the number of patients with ACA occlusions treated with EVT in our study. ACA occlusions in stroke may be more likely to be missed on baseline CTA, as the acute diagnostic workup for stroke patients typically focusses on the MCA branches [16]. In addition, due to variations in ACA anatomy and collateral blood flow, ACA strokes are often accompanied by non-specific symptoms and ACA occlusions may initially lead to little or no recognized sequelae [2, 3]. Careful evaluation of the ACA on imaging is warranted in all patients with stroke-like symptoms, specifically those presenting with disproportionate lower extremity weakness. Useful sequences for evaluating the ACA are maximum intensity projections—specifically the sagittal reconstructions—as well as multiphase CTA and/or CT Perfusion imaging (CTP) [3]. In recent years the increasing use of CTP has improved detection of large and medium vessel occlusions (LVO, MeVO) [10]. This may have led to increased detection and EVT of ACA occlusions in more recent years.
Data on outcomes of EVT in patients with ACA occlusion are scarce. Most studies are retrospective and include a small number of patients, even when large patient databases are used [11,12,13]. Despite high reported percentages of successful recanalization, several studies report functional independence rates after treating ACA occlusions of less than 40% [11,12,13, 17]. As ACA occlusions tend to be classified as MeVO [18], some studies on outcomes in EVT-treated stroke patients with MeVO also included ACA occlusions [19, 20]. Several trials on EVT in MeVO are currently ongoing, most notably EndovaSCular TreAtment to imProve outcomEs for Medium Vessel Occlusions (ESCAPE-MeVO, NCT05151172), Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever (DISTALS, NCT05152524), EnDovascular Therapy Plus Best Medical Treatment (BMT) Versus BMT Alone for MedIum VeSsel Occlusion sTroke (DISTAL, NCT05029414), and Evaluation of Mechanical Thrombectomy in Acute Ischemic Stroke Related to a Distal Arterial Occlusion (DISCOUNT, NCT05030142). However, the inclusion of other types of MeVO such as MCA- M2-4 occlusions, ACP-P1-2, and PICA and AICA occlusions may affect the evidence on benefit of EVT for ACA occlusions. Most observational studies do not differentiate between primary ACA and secondary ACA occlusions (e.g., iatrogenic after intravenous thrombolysis or EVT) [3, 20]. In our study, the rate of successful reperfusion after EVT for primary ACA occlusions was only 44%, which is lower compared to other reported series (73–100%), though our rate of functional independence was in line with previous studies [11,12,13, 17, 21].
Technically, endovascular procedures in the ACA are more challenging compared to the MCA territory. Technical difficulty increases with more distal occlusions (i.e., A2/A3 compared to A1). Catheterizing the ACA from the distal ICA is more difficult due to its curved anatomy and interventionalists need to avoid crossing the anterior communicating artery. The lower recanalization percentage in this study may be explained by the high number of patients with A2 occlusions (64%) in our cohort. The high number of patients with A2 occlusions may also explain the significantly lower NIHSS scores in patients with ACA occlusions at baseline.
Our study has limitations. First, the number of included patients with ACA occlusions was small, limiting the power and reliability of the comparisons made. The small group size also made further statistical modeling with covariate adjustment unfeasible. Second, the MR CLEAN Registry only included EVT-treated patients, so true treatment benefit of EVT compared to best medical care only could not be determined. ACA occlusions may occur more often, but may not be not treated with EVT in the absence of proven treatment benefit and clear guidelines, after which they would not be included in our current data set. Evaluation of consecutive EVT-treated and non-EVT-treated patients with ACA occlusions would be of great value. Third, the eTICI score used in the MR CLEAN Registry may be suboptimal in measuring the benefit of EVT in patients with ACA occlusions. The eTICI score is mostly used for assessing the MCA territory. As such, interpretation and scoring of the ACA territory may be subject to higher interobserver variability. Lastly, the data in our cohort span a period of several years, starting at the beginning of the widespread use of EVT in treating AIS. In recent years, EVT techniques have improved by using smaller or adjustable stent retrievers, increasingly more experienced interventionalists, and ongoing research [22]. Consequently, current interventions may actually lead to better recanalization and functional outcomes in patients with ACA occlusions [22]. The recent introduction of new generation small caliber catheters and low-profile stent retrievers has allowed access to more distal sites of ACA. The effect on outcome of EVT for distal (ACA) occlusions is currently being investigated in several clinical trials, such as DISTALS and DISCOUNT [23]. More data and analyses of existing data are needed to determine the benefit and safety of EVT in patients with ACA occlusions. Ideally, these data should be prospective in order to gather high-quality evidence on this topic.
Conclusion
In this Dutch national cohort of EVT-treated patients, patients with ACA occlusions were uncommon, occurring in only 0.2% of 4983 patients. Complication rates and functional outcomes were similar to those of EVT-treated patients with ICA and proximal MCA occlusions, though analyses were limited by the small ACA occlusion group sample size. Successful reperfusion was achieved in less than half of patients with ACA occlusions. These data may suggest that EVT is safe in ACA stroke, though more technically challenging. Prospective research is needed to confirm data on feasibility, safety, and outcomes of EVT for ACA strokes.
Disclosures
CBLMM received grants from CVON/Dutch Heart Foundation, Stryker, European Commission, TWIN, and Dutch Health Evaluation Program) and is a shareholder of Nico.Lab. DWJD received grants from Dutch Heart Foundation, Brain Foundation Netherlands, The Netherlands Organisation for Health Research and Development, Health Holland Top Sector Life Sciences & Health, Stryker, Penumbra Inc., Medtronic, Thrombolytic Science LLC, and Ceronovus. JMC received grants from Boehringer Ingelheim, Bayer, and Medtronic. PJvD received support from Stryker. WHvZ received personal support from Cerenovus, Stryker, Nicolab, and Philips. CPS received support from Neurophyxia BV. HBvdW received funding for consultancy from Bayer and TargED, and was paid to his institution. Others disclose nothing. MU received grants from Dutch Heart Foundation.
References
Toyoda K (2012) Anterior cerebral artery and Heubner’s artery territory infarction. Front Neurol Neurosci 30:120–122. https://doi.org/10.1159/000333607
Matos Casano HA, Tadi P, Ciofoaia GA (2021) Anterior Cerebral Artery Stroke. StatPearls Publishing, StatPearls Treasure Island FL
Goyal M, Cimflova P, Ospel JM, Chapot R (2021) Endovascular treatment of anterior cerebral artery occlusions. J Neurointerv Surg 13(11):1007–1011. https://doi.org/10.1136/neurintsurg-2021-017735. (Epub 2021 Jun 22)
Berkhemer OA, Fransen PS, Beumer D et al (2015) A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 372(1):11–20. https://doi.org/10.1056/NEJMoa1411587
Goyal M, Demchuk AM, Menon BK et al (2015) Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 372(11):1019–1030. https://doi.org/10.1056/NEJMoa1414905
Saver JL, Goyal M, Bonafe A et al (2015) Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 372(24):2285–2295. https://doi.org/10.1056/NEJMoa1415061
Campbell BC, Mitchell PJ, Kleinig TJ et al (2015) Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 372(11):1009–1018. https://doi.org/10.1056/NEJMoa1414792
Jovin TG, Chamorro A, Cobo E et al (2015) Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 372(24):2296–2306. https://doi.org/10.1056/NEJMoa1503780
Goyal M, Menon BK, van Zwam WH et al (2016) Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 387(10029):1723–1731. https://doi.org/10.1016/S0140-6736(16)00163-X
Bathla G, Pillenahalli Maheshwarappa R, Soni N, Hayakawa M, Priya S, Samaniego E, Ortega-Gutierrez S, Derdeyn CP (2022) CT perfusion maps improve detection of M2-MCA occlusions in acute ischemic stroke. J Stroke Cerebrovasc Dis. https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106473
Chung GH, Kwak HS, Park JS et al (2017) Manual aspiration thrombectomy with a penumbra catheter for acute anterior cerebral artery occlusion. Interv Neuroradiol 23:416–421
Uno J, Kameda K, Otsuji R et al (2018) Mechanical thrombectomy for acute anterior cerebral artery occlusion. World Neurosurg 120:e957–e961
Pfaff J, Herweh C, Pham M et al (2016) Mechanical thrombectomy of distal occlusions in the anterior cerebral artery: recanalization rates, periprocedural complications, and clinical outcome. AJNR Am J Neuroradiol 37:673–678
Cimflova P, Kappelhof M, Singh N, Kashani N, Ospel JM, McDonough R, Demchuk AM, Menon BK, Sakai N, Chen M, Fiehler J, Goyal M (2022) Factors influencing thrombectomy decision making for primary medium vessel occlusion stroke. J Neurointerv Surg 14(4):350–355. https://doi.org/10.1136/neurintsurg-2021-017472
Jansen IGH, Mulder MJHL, Goldhoorn RB, MR CLEAN Registry investigators (2018) Endovascular treatment for acute ischaemic stroke in routine clinical practice: prospective, observational cohort study (MR CLEAN Registry). BMJ. https://doi.org/10.1136/bmj.k949
Busby LP, Courtier JL, Glastonbury CM (2018) Bias in radiology: the how and why of misses and misinterpretations. Radiographics 38(1):236–247. https://doi.org/10.1148/rg.2018170107
Grossberg JA, Rebello LC, Haussen DC, Bouslama M, Bowen M, Barreira CM, Belagaje SR, Frankel MR, Nogueira RG (2018) Beyond Large Vessel Occlusion Strokes: Distal Occlusion Thrombectomy. Stroke 49(7):1662–1668. https://doi.org/10.1161/STROKEAHA.118.020567
Saver JL, Chapot R, Agid R et al (2020) Thrombectomy for distal, medium vessel occlusions: a consensus statement on present knowledge and promising directions. Stroke 51:2872–2884
Menon BK, Hill MD, Davalos A, Roos YBWEM, Campbell BCV, Dippel DWJ, Guillemin F, Saver JL, van der Lugt A, Demchuk AM, Muir K, Brown S, Jovin T, Mitchell P, White P, Bracard S, Goyal M (2019) Efficacy of endovascular thrombectomy in patients with M2 segment middle cerebral artery occlusions: meta-analysis of data from the HERMES Collaboration. J Neurointerv Surg 11(11):1065–1069. https://doi.org/10.1136/neurintsurg-2018-014678
Ospel JM, Goyal M (2021) A review of endovascular treatment for medium vessel occlusion stroke. J Neurointerv Surg 13(7):623–630. https://doi.org/10.1136/neurintsurg-2021-017321
Pfaff J, Herweh C, Pham M, Schieber S, Ringleb PA, Bendszus M, Möhlenbruch M (2016) Mechanical thrombectomy of distal occlusions in the anterior cerebral artery: recanalization rates, periprocedural complications, and clinical outcome. AJNR Am J Neuroradiol 37(4):673–678. https://doi.org/10.3174/ajnr.A4594. (Epub 2015 Nov 5)
Yeo LLL, Jing M, Bhogal P, Tu T, Gopinathan A, Yang C, Tan BYQ, Arnberg F, Sia CH, Holmin S, Andersson T (2021) Evidence-based updates to thrombectomy: targets, new techniques, and devices. Front Neurol 9(12):712527. https://doi.org/10.3389/fneur.2021.712527
Saver JL, Chapot R, Agid R, Hassan A, Jadhav AP, Liebeskind DS et al (2020) Thrombectomy for distal, medium vessel occlusions: a consensus statement on present knowledge and promising directions. Stroke 51:2872–2884. https://doi.org/10.1161/STROKEAHA.120.028956
Funding
Landsteiner Institute.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
Diederik W.J. Dippel received grants from the Dutch Heart Foundation, Brain Foundation Netherlands, The Netherlands Organisation for Health Research and Development, Health Holland Top Sector Life Sciences & Health, Stryker, Penumbra Inc., Medtronic, Thrombolytic Science LLC, and Ceronovus. Jonathan M. Coutinho received grants from Boehringer Ingelheim, Bayer, and Medtronic. Wim H. van Zwam received funding from Cerenovus, Stryker, Nicolab, and Philips. H Bart van der Worp received funding for consultancy from Bayer and TargED, paid to his institution. Cacha M.P.C.D. Peeters-Scholte received funding from Neurophyxia B.V. All other authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Appendix
Appendix
MR CLEAN Registry investigators:
Executive committee
Diederik W.J. Dippel1; Aad van der Lugt2; Charles B.L.M. Majoie3; Yvo B.W.E.M. Roos4; Robert J. van Oostenbrugge5,44; Wim H. van Zwam6,44; Jelis Boiten14; Jan Albert Vos8
Study coordinators
Ivo G.H. Jansen3; Maxim J.H.L. Mulder1,2; Robert- Jan B. Goldhoorn5,6,44; Kars C.J. Compagne2; Manon Kappelhof3; Josje Brouwer4; Sanne J. den Hartog1,2,40; Wouter H. Hinsenveld 5,6; Lotte van den Heuvel1,40.
Local principal investigators
Diederik W.J. Dippel1; Bob Roozenbeek1; Aad van der Lugt2; Pieter Jan van Doormaal2, Charles B.L.M. Majoie3; Yvo B.W.E.M. Roos4; Bart J. Emmer3; Jonathan M. Coutinho4; Wouter J. Schonewille7; Jan Albert Vos8; Marieke J.H. Wermer9; Marianne A.A. van Walderveen10; Adriaan C.G.M. van Es10; Julie Staals5,44; Robert J. van Oostenbrugge5,44; Wim H. van Zwam6,44; Jeannette Hofmeijer11; Jasper M. Martens12; Geert J. Lycklama à Nijeholt13; Jelis Boiten14; Sebastiaan F. de Bruijn15; Lukas C. van Dijk16; H. Bart van der Worp17; Rob H. Lo18; Ewoud J. van Dijk19; Hieronymus D. Boogaarts20; J. de Vries22; Paul L.M. de Kort21; Julia van Tuijl21; Issam Boukrab26; Jo P. Peluso26; Puck Fransen22; Jan S.P. van den Berg22; Heleen M. den Hertog22; Boudewijn A.A.M. van Hasselt23; Leo A.M. Aerden24; René J. Dallinga25; Maarten Uyttenboogaart28; Omid Eschgi29; Reinoud P.H. Bokkers29; Tobien H.C.M.L. Schreuder30; Roel J.J. Heijboer31; Koos Keizer32; Rob A.R. Gons32; Lonneke S.F. Yo33; Emiel J.C. Sturm35,47, Tomas Bulut35; Paul J.A.M. Brouwers34; Anouk D. Rozeman42; Otto Elgersma41, Michel J.M. Remmers43; Thijs E.A.M. de Jong46.
Imaging assessment committee
Charles B.L.M. Majoie3(chair); Wim H. van Zwam6,44; Aad van der Lugt2; Geert J. Lycklama à Nijeholt13; Marianne A.A. van Walderveen10; Marieke E.S. Sprengers3; Sjoerd F.M. Jenniskens27; René van den Berg3; Albert J. Yoo38; Ludo F.M. Beenen3; Alida A. Postma6.45; Stefan D. Roosendaal3; Bas F.W. van der Kallen13; Ido R. van den Wijngaard13; Adriaan C.G.M. van Es10; Bart J. Emmer,3; Jasper M. Martens12; Lonneke S.F. Yo33; Jan Albert Vos8; Joost Bot36; Pieter-Jan van Doormaal2; Anton Meijer27; Elyas Ghariq13; Reinoud P.H. Bokkers29; Marc P. van Proosdij37; G. Menno Krietemeijer33; Jo P. Peluso26; Hieronymus D. Boogaarts20; Rob Lo18; Wouter Dinkelaar41; Auke P.A. Appelman29; Bas Hammer16; Sjoert Pegge27; Anouk van der Hoorn29; Saman Vinke20; Sandra Cornelissen2; Christiaan van der Leij6; Rutger Brans6; Jeanette Bakker41; Maarten Uyttenboogaart28; Miou Koopman3; Lucas Smagge2; Olvert A. Berkhemer1,3,6; Jeroen Markenstein3; Eef Hendriks3; Patrick Brouwer10; Dick Gerrits35.
Writing committee
Diederik W.J. Dippel1(chair); Aad van der Lugt2; Charles B.L.M. Majoie3; Yvo B.W.E.M. Roos4; Robert J. van Oostenbrugge5,44; Wim H. van Zwam6,44; Geert J. Lycklama à Nijeholt13; Jelis Boiten14; Jan Albert Vos8; Wouter J. Schonewille7; Jeannette Hofmeijer11; Jasper M. Martens12; H. Bart van der Worp17; Rob H. Lo18
Adverse event committee
Robert J. van Oostenbrugge5,44(chair); Jeannette Hofmeijer11; H. Zwenneke Flach23
Trial methodologist
Hester F. Lingsma40
Research nurses / local trial coordinators
Naziha el Ghannouti1; Martin Sterrenberg1; Wilma Pellikaan7; Rita Sprengers4; Marjan Elfrink11; Michelle Simons11; Marjolein Vossers12; Joke de Meris14; Tamara Vermeulen14; Annet Geerlings19; Gina van Vemde22; Tiny Simons30; Gert Messchendorp28; Nynke Nicolaij28; Hester Bongenaar32; Karin Bodde24; Sandra Kleijn34; Jasmijn Lodico34; Hanneke Droste34; Maureen Wollaert5; Sabrina Verheesen5; D. Jeurrissen5; Erna Bos9; Yvonne Drabbe15; Michelle Sandiman15; Nicoline Aaldering11; Berber Zweedijk17; Jocova Vervoort21; Eva Ponjee22; Sharon Romviel19; Karin Kanselaar19; Denn Barning10 ; Laurine van der Steen3.
Clinical/imaging data aquisition
Esmee Venema40; Vicky Chalos1,40; Ralph R. Geuskens3; Tim van Straaten19; Saliha Ergezen1; Roger R.M. Harmsma1; Daan Muijres1; Anouk de Jong1; Olvert A. Berkhemer1,3,6; Anna M.M. Boers3,39; J. Huguet3; P.F.C. Groot3; Marieke A. Mens3; Katinka R. van Kranendonk3; Kilian M. Treurniet3; Manon L. Tolhuisen3,39; Heitor Alves3; Annick J. Weterings3; Eleonora L.F. Kirkels3; Eva J.H.F. Voogd11; Lieve M. Schupp3; Sabine L. Collette28,29; Adrien E.D. Groot4; Natalie E. LeCouffe4; Praneeta R. Konduri39; Haryadi Prasetya39; Nerea Arrarte-Terreros39; Lucas A. Ramos39 ; Nikki Boodt1,2,40; Anne F.A.V Pirson5; Agnetha A.E. Bruggeman3; Nadinda A.M. van der Ende 1,2, Rabia Deniz3, Susanne G.H. Olthuis5,44, Floor Pinckaers6,44
List of affiliations
Department of Neurology1, Radiology2, Public Health40, Erasmus MC University Medical Center;
Department of Radiology and Nuclear Medicine3, Neurology4, Biomedical Engineering & Physics39, Amsterdam UMC, location University of Amsterdam;
Department of Neurology5, Radiology & Nuclear Medicine6, Maastricht University Medical Center+; School for Cardiovascular Diseases Maastricht (CARIM)44; and MHeNs School for Mental Health and Neuroscience, Maastricht, the Netherlands45;Department of Neurology7, Radiology8, Sint Antonius Hospital, Nieuwegein;
Department of Neurology9, Radiology10, Leiden University Medical Center;
Department of Neurology11, Radiology12, Rijnstate Hospital, Arnhem; Department of Radiology13, Neurology14, Haaglanden MC, the Hague;
Department of Neurology15, Radiology16, HAGA Hospital, the Hague; Department of Neurology17, Radiology18, University Medical Center Utrecht; Department of Neurology19, Neurosurgery20, Radiology27, Radboud University Medical Center, Nijmegen;
Department of Neurology21, Radiology26, Elisabeth-TweeSteden ziekenhuis, Tilburg;
Department of Neurology22, Radiology23, Isala Klinieken, Zwolle;
Department of Neurology24, Radiology25, Reinier de Graaf Gasthuis, Delft;
Department of Neurology28, Radiology29, University Medical Center Groningen;
Department of Neurology30, Radiology31, Zuyderland Medical Center, Heerlen;
Department of Neurology32, Radiology33, Catharina Hospital, Eindhoven;
Department of Neurology34, Radiology35, Medisch Spectrum Twente, Enschede, (currently Deventer Hospital47);
Department of Radiology36, Amsterdam UMC, Vrije Universiteit van Amsterdam, Amsterdam;
Department of Radiology37, Noordwest Ziekenhuisgroep, Alkmaar;
Department of Radiology38, Texas Stroke Institute, Texas, United States of America;
Department of Neurology42, Radiology41, Albert Schweitzer Hospital, Dordrecht;
Department of Neurology43, Radiology46, Amphia Hospital, Breda.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Vos, E., Kappelhof, M., den Hartog, S.J. et al. Endovascular treatment of patients with stroke caused by anterior cerebral artery occlusions. Acta Neurol Belg 124, 621–630 (2024). https://doi.org/10.1007/s13760-023-02395-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13760-023-02395-8